Long-term Outcomes Following IGRT for Localized Prostate Cancer: Dose Escalation to SPECT/CT Determined Biologic Target Volumes and the bDFS Predictive Value of Capromab Pendetide

R.J Ellis,D.A Kaminsky,E.H Zhou,P Fu,A Brelin,P.F Faulhaber,D Bodner

doi:10.1016/j.ijrobp.2009.07.124

Long-term Outcomes Following IGRT for Localized Prostate Cancer: Dose Escalation to SPECT/CT Determined Biologic Target Volumes and the bDFS Predictive Value of Capromab Pendetide

R.J Ellis, D.A Kaminsky + Show 5 more

Open Access

https://doi.org/10.1016/j.ijrobp.2009.07.124

Copy DOI

Journal: International Journal of Radiation Oncology, Biology, Physics	Publication Date: Oct 3, 2009
Citations: 1

Affiliation: Case Western Reserve University, Aultman Hospital, Northeast Ohio Medical University, Ohio University

#Diagnosis Of Localized Prostate Cancer #Capromab Pendetide + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To evaluate the clinical utility of coregistered SPECT capromab pendetide and CT image sets (SPECT/CT) to identify biologic target volumes (BTV) for dose escalation, and to predict biochemical disease-free survival (bDFS) in a cohort of patients with a clinical diagnosis of localized prostate cancer.

Full Text